Results 161 to 170 of about 2,738,308 (324)

Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes.

British Journal of Clinical Pharmacology, 1998
V. Eagling, J. Tjia, D. Back
semanticscholar   +1 more source

Takayasu Arteritis in a G6PD Deficient Female Patient With Recurrent Axillary Artery Stenosis: A Case Report

Clinical Case Reports, Volume 14, Issue 9, September 2026.
ABSTRACT Takayasu arteritis should be suspected in young females with limb claudication, absent pulses, recurrent arterial stenosis, and elevated inflammatory markers. Early diagnosis is crucial to prevent complications. In G6PD‐deficient females, treatment must be modified, as specific immunosuppressants, like cyclophosphamide, can induce hemolysis ...
Junaid Imran, Mohammad Zohaib Rehman, Muhammad Osama, Safeena Khan, Pawan Kumar Thada   +4 more
wiley   +1 more source

Protein Abundance of Hydrolytic Drug Metabolizing Enzymes in Different Tissues and across Species. [PDF]

J Med Chem
Subash S, Ahire D, Jones RS, Ma B, Tian Y, Wang T, Khojasteh SC, Murray BP, Stresser DM, Taub M, Prasad B.   +10 more
europepmc   +1 more source

The Roles of EETs in Neurological Disorders

CNS Neuroscience &Therapeutics, Volume 32, Issue 9, September 2026.
Epoxyeicosatrienoic acids (EETs), derived from arachidonic acid (ARA) via cytochrome P450 (CYP450) enzymes, are produced in nearly all human tissues and exert a wide range of beneficial effects. This review summarizes the roles and potential mechanisms of EETs in neurological disorders, with a focus on cerebrovascular diseases, epilepsy, Parkinson's ...
Rong Tang, Mengya Li, Banglian Hu, Guoqiang Fei, Honghua Zheng, Xin Wang, Jing Ding   +6 more
wiley   +1 more source

Phenols: From Replacing to Embracing. [PDF]

ChemMedChem
Ouvry G.
europepmc   +1 more source

Payload‐Based Clinical Pharmacology Review of Approved Antibody–Drug Conjugates: Commonalities and Considerations for Streamlined Development

Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 614-638, September 2026.
Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the potency of a cytotoxic drug. Thirteen ADCs, utilizing seven unique cytotoxic payloads and targeting 11 distinct antigens, are currently approved by the US Food and Drug Administration as of June 2025, representing a rapidly growing and highly promising class of anticancer ...
Sijie Lu, Qingqing Xiao, Lixuan Qian, Siyuan Sun, Zhu Zhou, Michael Z. Liao, Chunze Li   +6 more
wiley   +1 more source

In Vivo Metabolite Formation and In Vitro Cytochrome P450-Mediated Metabolism of Vonoprazan in Horses. [PDF]

Metabolites
Morales CJ, Mckemie DS, Neupane JB, Knych HK.   +3 more
europepmc   +1 more source

Application of Virtual Twin PBPK Models in Individuals with Obesity via CYP3A4 Phenotyping Using Endogenous Biomarker Data

Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 762-773, September 2026.
Plasma 4β‐hydroxycholesterol (4β‐OHC) normalized for the levels of its parent cholesterol (4β‐OHC/C) is an endogenous biomarker for hepatic CYP3A4. This study evaluated CYP3A4 activity longitudinally in individuals while their obesity status was changing. 4β‐OHC/C was measured pre‐surgery (n = 54) and 2 years after Roux‐en‐Y gastric bypass (n = 30) and
Nihan Izat, Haribhau Kangne, Rasmus Jansson‐Löfmark, Jens K. Hertel, Amin Rostami‐Hodjegan, Ida Robertsen, Aleksandra Galetin   +6 more
wiley   +1 more source

A chemically optimized, GalNAc-conjugated siRNA targeting HSD17B13 demonstrates efficacy in a human 3D organoid model of MASH, showcasing an alternative to animal testing. [PDF]

PLoS One
Meng Q, Wang X, Zhang Y, Pushpakom S, Yang J, Feng H, Wang M.   +6 more
europepmc   +1 more source

From Executor to Orchestrator: The Pharmacology Scientist in the Age of Agentic AI

Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 648-662, September 2026.
Drug development productivity has not improved despite five decades of computational advancement, with the probability that a compound entering Phase I achieving regulatory approval remaining near 10%. Each automation wave increased throughput while leaving the interpretive bottleneck intact; scientists continued to formulate questions, evaluate ...
Michael McCoy, Matthew McCoy
wiley   +1 more source